Clinical Trials Browser

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT07416409 2026-02-18

Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer

Completed

80 enrolled

Breast

Breast Neoplasms, Neoplasms

NCT05786716 2025-12-02

DETERMINE

Phase 2/3 Recruiting

30 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther hematologic neoplasmThoracic

Urinary Bladder Neoplasms, Gallbladder Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Skin Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms

NCT05722886 2025-11-24

DETERMINE

Phase 2/3 Recruiting

825 enrolled

LymphoidOther hematologic neoplasm

Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Hematologic Neoplasms

NCT04341181 2025-07-25

ProTarget

Phase 2 Recruiting

300 enrolled

Tumor-Agnostic

Neoplasms

NCT02925234 2024-01-24

DRUP

Phase 2 Recruiting

1,550 enrolled

Tumor-Agnostic

Neoplasms

NCT05912062 2023-09-29

BiOnHER

Unknown

80 enrolled

Breast

Breast Neoplasms, Neoplasms

Clinical Trials

TAPUR

I-SPY

Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer

DETERMINE

DETERMINE

ProTarget

DRUP

BiOnHER